Gene expression profiling in MDS and AML: potential and future avenues

K Theilgaard-Mönch; J Boultwood; S Ferrari; K Giannopoulos; J M Hernandez-Rivas; A Kohlmann; M Morgan; B Porse; E Tagliafico; C M Zwaan; J Wainscoat; M M Van den Heuvel-Eibrink; K Mills; L Bullinger; K Theilgaard-Mönch; J Boultwood; S Ferrari; K Giannopoulos; J M Hernandez-Rivas; A Kohlmann; M Morgan; Bo T Porse; E Tagliafico; C M Zwaan; J Wainscoat; M M Van den Heuvel-Eibrink; K Mills; L Bullinger

doi:10.1038/leu.2011.48

Gene expression profiling in MDS and AML: potential and future avenues

K Theilgaard-Mönch, J Boultwood, S Ferrari, K Giannopoulos, J M Hernandez-Rivas, A Kohlmann, M Morgan, B Porse, E Tagliafico, C M Zwaan, J Wainscoat, M M Van den Heuvel-Eibrink, K Mills, L Bullinger, K Theilgaard-Mönch, J Boultwood, S Ferrari, K Giannopoulos, J M Hernandez-Rivas, A KohlmannM Morgan, Bo T Porse, E Tagliafico, C M Zwaan, J Wainscoat, M M Van den Heuvel-Eibrink, K Mills, L Bullinger

51 Citations (Scopus)

Abstract

Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.

Original language	English
Journal	Leukemia
Volume	25
Issue number	6
Pages (from-to)	909-20
Number of pages	12
ISSN	0887-6924
DOIs	https://doi.org/10.1038/leu.2011.48
Publication status	Published - Jun 2011

Access to Document

10.1038/leu.2011.48

Cite this

Theilgaard-Mönch, K., Boultwood, J., Ferrari, S., Giannopoulos, K., Hernandez-Rivas, J. M., Kohlmann, A., Morgan, M., Porse, B., Tagliafico, E., Zwaan, C. M., Wainscoat, J., Van den Heuvel-Eibrink, M. M., Mills, K., Bullinger, L., Theilgaard-Mönch, K., Boultwood, J., Ferrari, S., Giannopoulos, K., Hernandez-Rivas, J. M., ... Bullinger, L. (2011). Gene expression profiling in MDS and AML: potential and future avenues. Leukemia, 25(6), 909-20. https://doi.org/10.1038/leu.2011.48

Theilgaard-Mönch, K, Boultwood, J, Ferrari, S, Giannopoulos, K, Hernandez-Rivas, JM, Kohlmann, A, Morgan, M, Porse, B, Tagliafico, E, Zwaan, CM, Wainscoat, J, Van den Heuvel-Eibrink, MM, Mills, K, Bullinger, L, Theilgaard-Mönch, K, Boultwood, J, Ferrari, S, Giannopoulos, K, Hernandez-Rivas, JM, Kohlmann, A, Morgan, M, Porse, BT, Tagliafico, E, Zwaan, CM, Wainscoat, J, Van den Heuvel-Eibrink, MM, Mills, K & Bullinger, L 2011, 'Gene expression profiling in MDS and AML: potential and future avenues', Leukemia, vol. 25, no. 6, pp. 909-20. https://doi.org/10.1038/leu.2011.48

@article{cab8ada279494199beeaa4922bac980c,

title = "Gene expression profiling in MDS and AML: potential and future avenues",

abstract = "Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.",

author = "K Theilgaard-M{\"o}nch and J Boultwood and S Ferrari and K Giannopoulos and Hernandez-Rivas, {J M} and A Kohlmann and M Morgan and B Porse and E Tagliafico and Zwaan, {C M} and J Wainscoat and {Van den Heuvel-Eibrink}, {M M} and K Mills and L Bullinger and K Theilgaard-M{\"o}nch and J Boultwood and S Ferrari and K Giannopoulos and Hernandez-Rivas, {J M} and A Kohlmann and M Morgan and Porse, {Bo T} and E Tagliafico and Zwaan, {C M} and J Wainscoat and {Van den Heuvel-Eibrink}, {M M} and K Mills and L Bullinger",

year = "2011",

month = jun,

doi = "10.1038/leu.2011.48",

language = "English",

volume = "25",

pages = "909--20",

journal = "Leukemia",

issn = "0887-6924",

publisher = "nature publishing group",

number = "6",

}

TY - JOUR

T1 - Gene expression profiling in MDS and AML: potential and future avenues

AU - Theilgaard-Mönch, K

AU - Boultwood, J

AU - Ferrari, S

AU - Giannopoulos, K

AU - Hernandez-Rivas, J M

AU - Kohlmann, A

AU - Morgan, M

AU - Porse, B

AU - Tagliafico, E

AU - Zwaan, C M

AU - Wainscoat, J

AU - Van den Heuvel-Eibrink, M M

AU - Mills, K

AU - Bullinger, L

AU - Theilgaard-Mönch, K

AU - Boultwood, J

AU - Ferrari, S

AU - Giannopoulos, K

AU - Hernandez-Rivas, J M

AU - Kohlmann, A

AU - Morgan, M

AU - Porse, Bo T

AU - Tagliafico, E

AU - Zwaan, C M

AU - Wainscoat, J

AU - Van den Heuvel-Eibrink, M M

AU - Mills, K

AU - Bullinger, L

PY - 2011/6

Y1 - 2011/6

N2 - Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.

AB - Today, the classification systems for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) already incorporate cytogenetic and molecular genetic aberrations in an attempt to better reflect disease biology. However, in many MDS/AML patients no genetic aberrations have been identified yet, and even within some cytogenetically well-defined subclasses there is considerable clinical heterogeneity. Recent advances in genomics technologies such as gene expression profiling (GEP) provide powerful tools to further characterize myeloid malignancies at the molecular level, with the goal to refine the MDS/AML classification system, incorporating as yet unknown molecular genetic and epigenetic pathomechanisms, which are likely reflected by aberrant gene expression patterns. In this study, we provide a comprehensive review on how GEP has contributed to a refined molecular taxonomy of MDS and AML with regard to diagnosis, prediction of clinical outcome, discovery of novel subclasses and identification of novel therapeutic targets and novel drugs. As many challenges remain ahead, we discuss the pitfalls of this technology and its potential including future integrative studies with other genomics technologies, which will continue to improve our understanding of malignant transformation in myeloid malignancies and thereby contribute to individualized risk-adapted treatment strategies for MDS and AML patients.

U2 - 10.1038/leu.2011.48

DO - 10.1038/leu.2011.48

M3 - Journal article

C2 - 21445077

SN - 0887-6924

VL - 25

SP - 909

EP - 920

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Gene expression profiling in MDS and AML: potential and future avenues

Abstract

Access to Document

Fingerprint

Cite this